{"nctId":"NCT00067470","briefTitle":"Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI","startDateStruct":{"date":"2003-09"},"conditions":["Mucopolysaccharidosis VI"],"count":39,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"rhASB","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: N-acetylgalactosamine 4-sulfatase"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"N-acetylgalactosamine 4-sulfatase","otherNames":["rhASB"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Patient consent\n* Patient must be seven years of age or older\n* Patient must have documented biochemical or genetic proof of MPS VI\n* The patient must be able to walk independently at least 5 meters and no more than 270 meters in the first 6 minutes, or no more then 400 meters total in 12 minutes, in the screening 12-minute walk test\n* If female of childbearing potential, patient must have a negative pregnancy test\n\nExclusion Criteria\n\n* Patient is under consideration for or has undergone a successful bone marrow transplant (BMT)\n* Patient refuses or is unable to complete all screening evaluations\n* Pregnant or lactating patient\n* Patient has received an investigational drug within 30 days prior to study enrollment\n* Patient has been previously treated with rhASB\n* Patient has a medical condition, serious intercurrent illness, or other extenuating circumstance that may significantly confound study results or decrease study compliance\n* The patient has clinically significant spinal cord compression\n* The patient has known hypersensitivity to rhASB or to components of the active or placebo test solutions","healthyVolunteers":false,"sex":"ALL","minimumAge":"7 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in 12-minute Walk Test at 24 Weeks","description":"Number of meters walked in 12 minutes at week 24 minus number of meters walked in 12 minutes at baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":"154"},{"groupId":"OG001","value":"26","spread":"122"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 3-minute Stair Climb at 24 Weeks","description":"Number of stairs climbed per minute in 3 minutes at 24 weeks minus number of stairs climbed per minute in 3 minutes at baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"9.9"},{"groupId":"OG001","value":"2.7","spread":"6.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Urinary GAG (uGAG) at 24 Weeks","description":"Glycosaminoglycan (GAG) level measured in urine","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"346","spread":"128"},{"groupId":"OG001","value":"330","spread":"114"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":"35"},{"groupId":"OG001","value":"317","spread":"80"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":19},"commonTop":["Headache","Pyrexia","Arthralgia","Abdominal pain","Vomiting"]}}}